76 related articles for article (PubMed ID: 11766330)
1. [Introduction: chronic myelogenous leukemia leading advanced clinical oncology].
Asano S
Nihon Rinsho; 2001 Dec; 59(12):2309-10. PubMed ID: 11766330
[TBL] [Abstract][Full Text] [Related]
2. Current treatment approaches for chronic myelogenous leukemia.
Druker BJ
Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
[TBL] [Abstract][Full Text] [Related]
3. Recent advancements in the treatment of chronic myelogenous leukemia.
O'Dwyer ME; Mauro MJ; Druker BJ
Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
[TBL] [Abstract][Full Text] [Related]
4. [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
Jinnai I
Nihon Rinsho; 2002 Jan; 60(1):88-94. PubMed ID: 11808344
[TBL] [Abstract][Full Text] [Related]
5. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
7. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
9. Update: chronic myelogenous leukemia clinical practice guidelines.
O'Brien SM; Kantarjian H; Radich J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S29-40. PubMed ID: 19795574
[TBL] [Abstract][Full Text] [Related]
10. Signal transduction inhibitors (STI571): molecularly targeted therapy.
Corujo Y; Cáceres W
P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
[TBL] [Abstract][Full Text] [Related]
11. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor].
Ohno R
Nihon Rinsho; 2001 Dec; 59(12):2389-94. PubMed ID: 11766344
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors: a cure for chronic myeloid leukemia?
Zitella L
Clin J Oncol Nurs; 2000; 4(5):227-9. PubMed ID: 11111454
[TBL] [Abstract][Full Text] [Related]
14. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
[TBL] [Abstract][Full Text] [Related]
15. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myelogenous leukemia].
Ohnishi K
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
[TBL] [Abstract][Full Text] [Related]
17. Role of allogeneic transplantation in chronic myeloid leukemia.
Heim D; Gratwohl A
Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
[TBL] [Abstract][Full Text] [Related]
18. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
19. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
[TBL] [Abstract][Full Text] [Related]
20. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
